Treatment algorithms in stage IV melanoma

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Advanced melanoma treatment is evolving with molecular classification and new targeted therapies.
• Personalized medicine approaches are crucial for improving patient outcomes in stage IV melanoma.

Purpose of the Study:

• To develop a therapeutic algorithm for stage IV melanoma based on molecular profiling.
• To guide treatment selection for advanced melanoma patients using tumor genotyping.

Main Methods:

• Review of recent key studies on advanced melanoma therapies.
• Expert forum discussion to formulate a therapeutic strategy.
• Analysis of molecular targets like BRAF and KIT mutations.

Main Results:

• BRAF inhibitors (vemurafenib, dabrafenib) are recommended for BRAF-mutated melanoma.
• KIT inhibitors show efficacy in KIT-mutant tumors, particularly with exon 11 and 13 mutations.
• Ipilimumab and chemotherapy serve as options for specific patient groups and treatment lines.

Conclusions:

• Tumor genotyping is essential for selecting appropriate therapies in advanced melanoma.
• A multi-modal therapeutic algorithm incorporating targeted agents, immunotherapy, and chemotherapy is proposed.
• Clinical trial participation is strongly encouraged for long-term survival and potential cure.